# Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00702572** · PHASE1 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
- **DRUG:** Vorinostat, Bevacizumab, Carboplatin, Paclitaxel

## Key facts

- **NCT ID:** NCT00702572
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-09
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Low Enrollment
- **Last updated:** 2016-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702572, "Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00702572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*